Target intelligence / Profile preview

Porin A (PorA) P1.4 and associated outer membrane vesicle antigens of Neisseria meningitidis group B (PorA P1.4 OMV)

Target
PorA P1.4 OMV
Molecular classification
Bacterial outer membrane protein, Porin, Antigenic complex, Outer membrane vesicle (OMV)
01

Overview

Porin A (PorA) is a major class 1 outer membrane protein of Neisseria meningitidis, functioning as a selective cation-permeable channel essential for nutrient uptake and metabolic waste export (UniProt P0A105). The P1.4 variant refers to a specific serosubtype of the PorA protein, notably prevalent in epidemic strains such as the NZ98/254 strain responsible for the New Zealand meningococcal outbreak. Outer membrane vesicles (OMVs) are proteoliposomes naturally shed by the bacteria that contain PorA along with other critical antigens like PorB, Opa, and Opc, which play roles in adhesion and immune evasion (Holst et al., 2009, Vaccine). In therapeutic contexts, these OMVs are utilized as vaccine components to elicit a robust immune response. The primary mechanism of action involves the generation of bactericidal antibodies that target the variable regions of PorA, leading to complement-mediated lysis of the pathogen (Bambini et al., 2013, Vaccine). Because PorA is highly antigenically variable, OMV-based vaccines are often tailored to specific regional strains or combined with other recombinant proteins to broaden protection against serogroup B meningococci.

Other names
Class 1 outer membrane proteinPorin AMenB OMVP1.7-2,4MeNZB antigenNZ98/254 OMV
02

Mechanism of action

Induction of serum bactericidal antibodies (SBA) that facilitate complement-mediated killing of Neisseria meningitidis through recognition of PorA and other OMV-associated surface antigens (O'Hallahan et al., 2004, Lancet Infectious Diseases).

03

Biological functions

Nutrient transportMembrane permeabilityImmune responseBacterial adhesionCation-selective channel activity
04

Disease associations

InfectionMeningococcal diseaseMeningitisSepsis
05

Safety considerations

Reactogenicity (fever, injection site pain)Strain-specific coverage (antigenic variation of PorA)Potential for 'escape mutants' lacking specific PorA epitopes
06

Interacting drugs

Meningococcal Group B Vaccine (Bexsero)

2 more in the full profile.

07

Biomarkers

Serum bactericidal activity (hSBA) titersPorA-specific IgG levels

Beyond the preview

Go deeper on Porin A (PorA) P1.4 and associated outer membrane vesicle antigens of Neisseria meningitidis group B (PorA P1.4 OMV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Porin A (PorA) P1.4 and associated outer membrane vesicle antigens of Neisseria meningitidis group B (PorA P1.4 OMV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call